appendix IX 
Clinical Protocol 
Treatment Schema 
Admit the morning of administration of interleukin-2 (IL-2 ) -producing 
allogeneic melanoma cells (UISO-Mel-4-IL-2 ) 
5 x 10 8 UISO-Mel-4-IL-2 
cells in 5 ml of PBS injected intramuscularly 
, 7 
Simultaneously, two intradermal injections of 2 x 10 UISO-Mel-4-IL-2 
cells in 0.1 ml of PBS at a distance of 3 cm from the therapeutic injection 
site . 
Discharge patient 23 hours after immunization. 
Repeat injections every three weeks for four immunizations 
After first course, evaluate biweekly for laboratory evidence of an anti 
melanoma response; clinical status 
Failure to develop anti melanoma immunity and/or anti melanoma disease 
progression > off study 
Evidence of anti melanoma immunity and or tumor regression and the patient 
will receive four courses of injections over a period of one year. 
[344] 
Recombinant DNA Research, Volume 18 
